Science News
from research organizations

Roflumilast improves lung function after 6 months compared with placebo

Date:
October 22, 2012
Source:
American College of Chest Physicians
Summary:
Roflumilast was associated with significant improvements in lung function in patients with moderate and severe chronic obstructive pulmonary disease after six months of treatment compared with placebo.
Share:
       
FULL STORY

Roflumilast was associated with significant improvements in lung function in patients with moderate and severe chronic obstructive pulmonary disease (COPD) after 6 months of treatment compared with placebo. Roflumilast is approved to reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

To examine the drug's impact on lung function, researchers from multiple institutions, including Baylor College of Medicine; Takeda Pharmaceuticals International GmbH; and Forest Research Institute, randomized 4,746 subjects to roflumilast (pooled intent-to-treat [ITT], n= 2511; moderate COPD, n=1184; severe COPD, n=1217) or placebo (pooled ITT, n=2235; moderate COPD, n=1098; severe COPD, n=1062). Baseline demographics were similar between treatment groups.

At 6 months, roflumilast increased pre- and postbronchodilator FEV1 by 66 mL and 67 mL, respectively, compared with placebo. Roflumilast, compared with placebo, also increased pre- and postbronchodilator FEV1 in subjects with moderate and severe COPD.

This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 -- 25, in Atlanta, Georgia.


Story Source:

The above post is reprinted from materials provided by American College of Chest Physicians. Note: Materials may be edited for content and length.


Cite This Page:

American College of Chest Physicians. "Roflumilast improves lung function after 6 months compared with placebo." ScienceDaily. ScienceDaily, 22 October 2012. <www.sciencedaily.com/releases/2012/10/121022080928.htm>.
American College of Chest Physicians. (2012, October 22). Roflumilast improves lung function after 6 months compared with placebo. ScienceDaily. Retrieved August 5, 2015 from www.sciencedaily.com/releases/2012/10/121022080928.htm
American College of Chest Physicians. "Roflumilast improves lung function after 6 months compared with placebo." ScienceDaily. www.sciencedaily.com/releases/2012/10/121022080928.htm (accessed August 5, 2015).

Share This Page: